about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

An­oth­er PhI­II win in hand, Cara aims straight for pri­or­i­ty re­view of 'break­through' pru­ri­tus drug

6 years ago
R&D

Covid-19 roundup: The pan­dem­ic bear — You think a vac­cine and herd im­mu­ni­ty are just months away? Dream on, says ...

6 years ago
Coronavirus

Es­pe­ri­on strikes Japan deal for 'goldilock­s' cho­les­terol drug, bags $60M cash as pan­dem­ic forces vir­tu­al US roll­out

6 years ago
Deals

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

6 years ago
R&D
Coronavirus

Chi­nese an­ti­body mak­er, famed for Ebo­la cock­tail, notch­es $160M as it fo­cus­es on can­cer, au­toim­mune drugs

6 years ago
Financing
China

Re­port on one PhI­II remde­sivir study sends in­vestors in­to over­drive, adding bil­lions to Gilead­'s mar­ket cap

6 years ago
R&D
Coronavirus

Covid-19 roundup: Blis­tered by heat­ed re­ac­tion to their role in the out­break, Bio­gen makes amends with Covid-19 ...

6 years ago
Coronavirus

FDA stamps OK on Uro­Gen's chemo gel — putting Liz Bar­rett and team's com­mer­cial chops to test amid pan­dem­ic

6 years ago
Pharma
FDA+

Ex-GSK chief An­drew Wit­ty sum­moned back to the front­lines of vac­cine de­vel­op­ment at em­bat­tled WHO

6 years ago
R&D

LEO Phar­ma mounts an­oth­er chal­lenge to the eczema gi­ants, bet­ting $40M cash on a drug from Chi­na

6 years ago
Deals

Tout­ing new way of min­ing neu­ro tar­gets, Take­da spin­out draws $45M from GV, Bill Gates, Fore­site

6 years ago
Financing

Plough­ing through a crowd­ed PD-(L)1 mar­ket, BeiGene loads up on promis­ing lung can­cer da­ta

6 years ago
R&D
China

'Why not do it now?' Al­ny­lam's John Maraganore takes up Black­stone's $2B of­fer to build the fi­nal 'bridge to ...

6 years ago
Deals

Covid-19 roundup: Tri­al of Trump's fa­vorite Covid-19 drug nixed on ear­ly death risk; Is An­tho­ny Fau­ci on thin ice ...

6 years ago
Coronavirus

Hunt­ing a full OK for Baven­cio in front­line blad­der can­cer, Pfiz­er, Mer­ck KGaA re­ceive VIP treat­ment at FDA

6 years ago
Pharma
FDA+

Qim­ing's Chi­na-fo­cused $1.1B new fund brings glob­al haul to $5B with­in 1 week — but the dis­tri­b­u­tion won't be even

6 years ago
Financing
China

FDA needs three more months to re­view Roche's SMA drug — giv­ing Bio­gen, No­var­tis some re­lief

6 years ago
FDA+

Mer­ck-part­nered an­ti­body mak­er read­ies $300M IPO as HKEX picks up pace

6 years ago
Financing
China

Ready to de­clare a de­fin­i­tive come­back in two months, Im­munomedics stops PhI­II ear­ly, re­cruits new CEO

6 years ago
People
R&D

Bris­tol My­ers Squibb, Ac­celeron rack up sec­ond OK for Re­blozyl, on­to block­buster sta­tus

6 years ago
Pharma
FDA+

Lil­ly Asia Ven­tures co-leads $100M+ round for Chi­nese biotech and its late-stage lu­pus drug

6 years ago
Financing
China

Ahead of US IPO, Leg­end Biotech adds $150M, top-tier in­vestors to back CAR-T pipeline

6 years ago
Financing
R&D

Mer­ck scores new ad­vance on tu­mor-ag­nos­tic front as Keytru­da beat chemo-based reg­i­mens in a type of col­orec­tal can­cer

6 years ago
R&D
Pharma

No­var­tis can­cels $1B sale of gener­ics af­ter an­titrust con­cerns forced de­lays

6 years ago
Deals
First page Previous page 77787980818283 Next page Last page
A service from the Financial Times